
Prof. Ronit Satchi-Fainaro in her lab
Researchers at Tel Aviv University and the University of Lisbon have discovered a potentially new immunotherapy, which may lead to more affordable and effective treatments. Immunotherapy activates the patient’s immune system to fight cancer cells.
In this significant step in the fight against cancer, the researchers used computational and bioinformatic systems to discover a tiny molecule which can enter a solid tumor. Thanks to its low molecular weight, the molecule outperforms existing antibodies that are used as the key component in many cancer immunotherapies today. The molecule is also small enough that it may one day be administered in a pill form, saving stressful and time-consuming trips to the hospital.
Behind the groundbreaking development is an international team of researchers led by Prof. Ronit Sachi-Fainaro, Director of the Center for Cancer Biology Research and Head of the Laboratory for Cancer Research and Nanomedicine at the Sackler Faculty of Medicine at Tel Aviv University, along with Prof. Helena Florindo and Prof. Rita Guedes from the Research Institute for Medicines at the Faculty of Pharmacy, University of Lisbon. The results of the study were published in the Journal for ImmunoTherapy of Cancer.
Making Effective Immunotherapy Accessible
Immunotherapies can significantly improve patient recovery rates, without the severe side effects that accompany treatments such as chemotherapy. Immunotherapies often make use of antibodies, which are similar to proteins produced by the immune system to destroy infection-causing organisms. However, while lab-grown antibodies created to fight cancer have demonstrated some success, they are costly and not always effective.
“I believe that in the future, the small molecule will be commercially available and will make immunotherapy affordable for cancer patients.”
Considering these challenges, TAU and University of Lisbon researchers used computational, bioinformatics and data analysis tools to evaluate thousands of molecular structures. They discovered a list of potential candidates and used the best structure they found to synthesize the new, small molecule which has successfully activated immune cells against cancer cells in lab models, including patient-derived ones.
The creation of this small molecule builds on the research of Nobel Prize winners James Allison and Tasuku Honjo, who originally developed the CTLA-4 and PD-1 antibodies, respectively, which are used in today’s cancer immunotherapies. The two discovered that immune cells are essentially disabled by particular proteins found in cancer and immune cells. The protein called PD-L1 is found in cancer cells, and paralyzes immune cells by binding to a protein on these cells called PD-1. Honjo’s antibodies neutralize the PD-1/PD-L1 protein bond, allowing the immune system to attack the cancer.
“Patients will probably be able to take it at home, orally, without the need for IV administration in the hospital.”
Prof. Satchi-Fainaro, head of the TAU research team and a 2020 Kadar Family Award winner, explains that whereas lab-grown antibodies have complex structures and are expensive to produce, the new molecule was synthesized with simple equipment at a low cost. “I believe that in the future, the small molecule will be commercially available and will make immunotherapy affordable for cancer patients.”
The small molecule is also better equipped to penetrate a solid tumor than previous treatments. The antibodies used for current treatments enter a tumor via its blood vessels. “If there are fewer blood vessels in a particular area of ??the tumor, the antibody will not be able to get inside. The small molecule, on the other hand, diffuses, and is therefore not entirely dependent on the tumor’s blood vessels or on its hyper-permeability,” says Prof. Satchi-Fainaro. “Another advantage of the small molecule is that it may be available in a format that patients will probably be able to take at home, orally, without the need for intravenous injections in the hospital.”
Original Article: Tiny Molecule Makes Big Impact on Cancer Treatment
More from: Tel Aviv University | University of Lisbon
The Latest Updates from Bing News
Go deeper with Bing News on:
Immunotherapy
- Health Care Down as FDA Probes Immunotherapy Treatments -- Health Care Roundup
Health-care companies fell as traders hedged their bets on the outlook for growth in the sector. The U.S. Food and Drug Administration is ...
- Stress May Inhibit Immunotherapy’s Efficacy in Treating Cancer
Psychological stress may inhibit the efficacy of immune-checkpoint inhibitor (ICI) therapy among patients with advanced non–small cell lung cancer (NSCLC), according to findings from the STRESS-LUNG-1 ...
- CAR T Cell Immunotherapy And The Quiet Hope For A Universal Cancer Treatment
All of us have to deal with the looming threat of developing cancer during our lifetime, no matter how good our genetics are, or how healthy our lifestyle is. Despite major improvements to the way ...
- Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitis
Researchers from Skoltech contributed to a large study made by colleagues from Pirogov Russian National Research Medical University, Shemyakin-Ovchinnikov Institute of bioorganic chemistry and other ...
- Harnessing the Power of the Immune System: Advances in Cancer Immunotherapy
This article will explore the role of the immune system and immune evasion in cancer and will discuss how the immune system can be exploited therapeutically and the recent advances in cancer ...
Go deeper with Bing News on:
Cancer immunotherapy
- Stress May Inhibit Immunotherapy’s Efficacy in Treating Cancer
Psychological stress may inhibit the efficacy of immune-checkpoint inhibitor (ICI) therapy among patients with advanced non–small cell lung cancer (NSCLC), according to findings from the STRESS-LUNG-1 ...
- Healthy Tissues ‘Hold Important Clues’ About Cancer Recurrence Risk
So, that means the cancer cells are out there, you take out the bulk of the tumor, you think you're cured, but there's this presence of tumor cells that the immune system perhaps recognizes. So, ...
- CAR T Cell Immunotherapy And The Quiet Hope For A Universal Cancer Treatment
All of us have to deal with the looming threat of developing cancer during our lifetime, no matter how good our genetics are, or how healthy our lifestyle is. Despite major improvements to the way ...
- Harnessing the Power of the Immune System: Advances in Cancer Immunotherapy
This article will explore the role of the immune system and immune evasion in cancer and will discuss how the immune system can be exploited therapeutically and the recent advances in cancer ...
- Immunotherapy drug proves promising for deadly small cell lung cancer
Researchers have published the results of a clinical trial evaluating the efficacy of an immunotherapy drug in treating a particularly aggressive form of lung cancer. Tarlatamab produced promising ...